SeekingAlpha · Aug 19, 2026
Jade Biosciences: Duration Is The Real Product
Jade Biosciences targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence. Read more on JBIO stock here.
JB
NASDAQ · JBIO
Jade Biosciences, Inc.
Healthcare · Biotechnology
$19.90
Up+$0.05 (+0.25%)
Updated Sep 6, 2026, 11:18 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 484.17M
- P/E ratio
- -9
- Dividend yield
- 0.00%
- 52-week range
- $12.45 – $28.00
- Volume
- 605.02K
- Avg. volume
- 195K
Price performance
JBIO price history
1M range · 20 trading sessions · Daily adjusted prices
JBIO closed at $19.90 after 20 trading sessions, down 8.42% for the selected period.
- Last close
- $19.90
- Period change
- -8.42%
- Period low
- $19.85
- Period high
- $24.71
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $19.86 | $20.35 | $19.70 | $19.90 | 605.02K |
| Sep 3, 2026 | $21.00 | $21.265 | $19.76 | $19.85 | 1.38M |
| Sep 2, 2026 | $21.17 | $22.00 | $20.475 | $21.40 | 506.17K |
| Sep 1, 2026 | $21.32 | $21.615 | $20.73 | $21.02 | 516.64K |
| Aug 31, 2026 | $20.65 | $21.45 | $20.35 | $21.36 | 837.04K |
| Aug 28, 2026 | $21.065 | $21.40 | $20.81 | $20.84 | 357.94K |
| Aug 27, 2026 | $21.26 | $21.845 | $21.13 | $21.29 | 342.59K |
| Aug 26, 2026 | $22.40 | $22.40 | $21.195 | $21.33 | 355.91K |
| Aug 25, 2026 | $21.74 | $22.16 | $21.33 | $21.84 | 603.53K |
| Aug 24, 2026 | $21.27 | $21.775 | $20.395 | $21.33 | 595.72K |
| Aug 21, 2026 | $21.45 | $22.12 | $21.13 | $21.34 | 571.85K |
| Aug 20, 2026 | $23.815 | $23.815 | $20.70 | $21.23 | 936.62K |
| Aug 19, 2026 | $23.87 | $24.3297 | $22.43 | $22.55 | 789.06K |
| Aug 18, 2026 | $23.07 | $23.60 | $22.87 | $23.55 | 721.66K |
| Aug 17, 2026 | $24.60 | $24.94 | $23.30 | $23.45 | 671.57K |
| Aug 14, 2026 | $23.57 | $25.00 | $23.38 | $24.71 | 1.48M |
| Aug 13, 2026 | $23.52 | $24.09 | $23.02 | $23.81 | 1.09M |
| Aug 12, 2026 | $22.49 | $23.46 | $21.51 | $23.21 | 713.87K |
| Aug 11, 2026 | $22.07 | $22.5201 | $21.40 | $22.35 | 525.65K |
| Aug 10, 2026 | $21.92 | $23.05 | $21.43 | $21.73 | 634.99K |
Latest JBIO news
The latest Smart Investors Daily articles mentioning JBIO.
Stock researchCompany · Overview
JBIO research
Overview
Company profile and research snapshot.
Company profile
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $21.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Wedbush | Outperform | — |
| Aug 10, 2026 | BTIG | Buy | — |
| Jun 15, 2026 | UBS | Buy | — |
| Jun 2, 2026 | Wedbush | Outperform | — |
| Jun 1, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $45 to $47.
Benzinga · Aug 10, 2026
Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 11.63 percent increase over losses of $(0.86) per share
Benzinga · Jul 1, 2026
Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon; To Pay Paragon Low To Mid-Single-Digit Percentage Royalties On Net Sales Of Licensed Products; Paragon Barred From New Campaigns Targeting Licensed Target For At Least Five Years
-SEC Filing
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
